Caris Life Sciences, Inc. Common Stock
Here’s whether Caris Life Sciences, Inc. Common Stock (CAI) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+7.36% over 10 days); 3-month momentum positive (+68.9%). Concerns: RSI 83 — overbought, elevated pullback risk; weak 1-year return of -31.1%. Currently 38.2% off its 52-week high. Score: +3/7.
CAI is in a confirmed uptrend, trading above both its 50-day ($18.42) and 200-day ($20.94) moving averages. With an RSI of 82.6, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -31.1% compares to +20.5% for SPY (trailed the market by 51.6%). The current 38.2% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.